Status:
COMPLETED
Therapy Optimization in Multiple Sclerosis (MS)
Lead Sponsor:
Teva Neuroscience, Inc.
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to determine if higher compliance and adherence rates to drug therapy for MS result in better health outcomes than lower rates of therapy compliance and adherence.
Eligibility Criteria
Inclusion
- Male or female, 18 years of age or older, with a diagnosis of MS.
- Being treated with Glatiramer Acetate (GA) or (IFN)-β
- Receiving therapy from a participating Specialty Pharmacy
Exclusion
- Has any contraindication to GA or IFN-β therapy, including pregnancy, trying to become pregnant, or breast feeding during the study
- Has received an experimental drug in the last thirty (30) days other than Fampridine SR (4-aminopyridine or 4-AP)
- Unlikely to be able to participate for the full two years of the study
Key Trial Info
Start Date :
December 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2013
Estimated Enrollment :
2878 Patients enrolled
Trial Details
Trial ID
NCT00819000
Start Date
December 1 2008
End Date
January 1 2013
Last Update
January 29 2013
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Teva Investigational Site
Swartz Creek, Michigan, United States
2
Teva Investigational Site
Columbus, Ohio, United States
3
Teva Investigational Site
Carnegie, Pennsylvania, United States